Vanda Pharmaceuticals Inc. (VNDA)
| Market Cap | 404.30M |
| Revenue (ttm) | 216.11M |
| Net Income (ttm) | -220.47M |
| Shares Out | 59.11M |
| EPS (ttm) | -3.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,033,965 |
| Open | 6.78 |
| Previous Close | 6.79 |
| Day's Range | 6.76 - 7.02 |
| 52-Week Range | 3.81 - 9.94 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 14.90 (+117.84%) |
| Earnings Date | May 6, 2026 |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develop... [Read more]
Financial Performance
In 2025, Vanda Pharmaceuticals's revenue was $216.11 million, an increase of 8.72% compared to the previous year's $198.77 million. Losses were -$220.47 million, 1066.5% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price target is $14.9, which is an increase of 117.84% from the latest price.
News
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026...
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
WASHINGTON, April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification. ...
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the preventi...
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, toda...
Vanda Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
The company highlighted recent product approvals, robust late-stage pipeline progress, and a strong financial position. BYSANTI and Nereus launches are set for 2026, with significant revenue growth expected from psychiatry and consumer health portfolios.
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
WASHINGTON, March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a for...
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on ...
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are up during Wednesday's premarket session following the FDA's approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, as well ...
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics Li...
Vanda Pharmaceuticals stock's explosive rally may be more hype than substance
Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA's approval for its treatment of schizophrenia and bipolar I disorder. The BYSANTI ...
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading higher during the premarket session on Monday following the announcement of FDA approval for Bysanti (milsaperidone), a new treatment for bipola...
US FDA approves Vanda's psychiatric drug
The U.S. Food and Drug Administration has approved Vanda Pharmaceutical's drug for the treatment of two serious mental health conditions, the company said on Friday.
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a fi...
Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw 9% revenue growth to $216.1M, led by Fanapt's 24% sales increase and major regulatory wins, including Nereus approval. 2026 guidance projects $230–$260M revenue, with Fanapt driving growth and further investments in commercial and R&D activities.
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024 NEREUS...
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full...
Vanda Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a robust late-stage pipeline, with imminent catalysts including Bysanti's PDUFA in February 2026 and NEREUS's commercial launch. Significant growth is expected from new indications, especially in motion sickness, GLP-1, and MDD.
Vanda and Exante Data Combine in Strategic Merger
LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macr...
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Cen...
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.
US FDA approves Vanda Pharmaceuticals' motion sickness drug
Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the no...
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral...
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administr...
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
WASHINGTON , Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco...